Amendment: SEC Form SC 13D/A filed by BlackRock Municipal Income Fund Inc.
| BLACKROCK MUNICIPAL INCOME FUND, INC. | 
| (Name of Issuer) | 
| VARIABLE RATE DEMAND PREFERRED SHARES | 
| (Title of Class of Securities) | 
| 09262J201 | 
| (CUSIP Number) | 
| Bank of America Corporation Bank of America Corporate Center 100 N. Tryon Street Charlotte, North Carolina 28255 | 
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) | 
| April 26, 2022 | 
| (Date of Event which Requires Filing of this Statement) | 
| 1 | NAMES OF REPORTING PERSONS |  |  | ||
| Bank of America Corporation 56-0906609 |  |  | |||
|  |  | ||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | ☐ | ||
| (b) | ☒ | ||||
|  |  | ||||
| 3 | SEC USE ONLY |  |  | ||
|  |  |  | |||
|  |  | ||||
| 4 | SOURCE OF FUNDS (SEE INSTRUCTIONS) |  |  | ||
| WC |  |  | |||
|  |  | ||||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) |  | ☒ | ||
|  |  | ||||
|  |  | ||||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |  | ||
| Delaware |  |  | |||
|  |  | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER |  |  | |
| 0 |  |  | |||
|  |  | ||||
| 8 | SHARED VOTING POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 9 | SOLE DISPOSITIVE POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 10 | SHARED DISPOSITIVE POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |  | ☐ | ||
|  |  | ||||
|  |  | ||||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |  |  | ||
| 0% |  |  | |||
|  |  | ||||
| 14 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |  |  | ||
| HC |  |  | |||
|  |  | ||||
| 1 | NAMES OF REPORTING PERSONS |  |  | ||
| Banc of America Preferred Funding Corporation 75-2939570 |  |  | |||
|  |  | ||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | ☐ | ||
| (b) | ☒ | ||||
|  |  | ||||
| 3 | SEC USE ONLY |  |  | ||
|  |  |  | |||
|  |  | ||||
| 4 | SOURCE OF FUNDS (SEE INSTRUCTIONS) |  |  | ||
| WC |  |  | |||
|  |  | ||||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) |  | ☐ | ||
|  |  |  | |||
|  |  | ||||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |  | ||
| Delaware |  |  | |||
|  |  | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER |  |  | |
| 0 |  |  | |||
|  |  | ||||
| 8 | SHARED VOTING POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 9 | SOLE DISPOSITIVE POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 10 | SHARED DISPOSITIVE POWER |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |  | ||
| 0 |  |  | |||
|  |  | ||||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |  | ☐ | ||
|  |  |  | |||
|  |  | ||||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |  |  | ||
| 0% |  |  | |||
|  |  | ||||
| 14 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |  |  | ||
| CO |  |  | |||
|  |  | ||||
| Item 2. | Identity and Background | 
| Item 5. | Interest in Securities of the Issuer | 
| Item 7. | Material to be Filed as Exhibits | 
| Exhibit No. | Description | |
| Joint Filing Agreement, dated as of December 13, 2024, by and among the Reporting Persons. | 
| BANK OF AMERICA CORPORATION | ||
| By: | /s/ Andres Ortiz | |
| Name: Andres Ortiz | ||
| Title: Authorized Signatory | ||
| BANC OF AMERICA PREFERRED FUNDING CORPORATION | ||
| By: | /s/ Andres Ortiz | |
| Name: Andres Ortiz | ||
| Title: Authorized Signatory | ||
| Name | Position with Bank of America Corporation | Principal Occupation | ||
| Brian T. Moynihan | Chairman of the Board, Chief Executive Officer and Director | Chairman of the Board and Chief Executive Officer of Bank of America Corporation | ||
| Paul M. Donofrio | Vice Chair | Vice Chair of Bank of America Corporation | ||
| Thong M. Nguyen | Vice Chair, Head of Global Strategy & Enterprise Platforms | Vice Chair, Head of Global Strategy & Enterprise Platforms of Bank of America Corporation | ||
| Bruce R. Thompson | Vice Chair, Head of Enterprise Credit | Vice Chair, Head of Enterprise Credit of Bank of America Corporation | ||
| Dean C. Athanasia | President, Regional Banking | President, Regional Banking of Bank of America Corporation | ||
| James P. DeMare | President, Global Markets | President, Global Markets of Bank of America Corporation | ||
| Kathleen A. Knox | President, The Private Bank | President, The Private Bank of Bank of America Corporation | ||
| Matthew M. Koder | President, Global Corporate and Investment Banking | President, Global Corporate and Investment Banking of Bank of America Corporation | ||
| Bernard A. Mensah | President, International; CEO, Merrill Lynch International | President, International of Bank of America Corporation and CEO, Merrill Lynch International | ||
| Lindsay DeNardo Hans | President, Co-Head Merrill Wealth Management | President, Co-Head Merrill Wealth Management of Bank of America Corporation | ||
| Eric Schimpf | President, Co-Head Merrill Wealth Management | President, Co-Head Merrill Wealth Management of Bank of America Corporation | ||
| Aditya Bhasin | Chief Technology and Information Officer | Chief Technology and Information Officer of Bank of America Corporation | ||
| D. Steve Boland | Chief Administrative Officer | Chief Administrative Officer of Bank of America Corporation | ||
| Alastair Borthwick | Chief Financial Officer | Chief Financial Officer of Bank of America Corporation | 
| Sheri Bronstein | Chief Human Resources Officer | Chief Human Resources Officer of Bank of America Corporation | ||
| Geoffrey Greener | Chief Risk Officer | Chief Risk Officer of Bank of America Corporation | ||
| Thomas M. Scrivener | Chief Operations Executive | Chief Operations Executive of Bank of America Corporation | ||
| Lauren A. Mogensen | Global General Counsel | Global General Counsel of Bank of America Corporation | ||
| Lionel L. Nowell, III | Lead Independent Director | Lead Independent Director, Bank of America Corporation; Former Senior Vice President and Treasurer, PepsiCo, Inc. | ||
| Sharon L. Allen | Director | Former Chairman, Deloitte LLP | ||
| Jose E. Almeida | Director | Chairman, President and Chief Executive Officer of Baxter International Inc. | ||
| Pierre J.P. de Weck1 | Director | Former Chairman and Global Head of Private Wealth Management, Deutsche Bank AG | ||
| Arnold W. Donald | Director | Former President and Chief Executive Officer, Carnival Corporation & Carnival plc | ||
| Linda P. Hudson | Director | Former Executive Officer, The Cardea Group, LLC and Former President and Chief Executive Officer of BAE Systems, Inc. | ||
| Monica C. Lozano | Director | Lead Independent Director, Target Corporation; Former Chief Executive Officer, Former College Futures Foundation and Former Chairman, US Hispanic Media Inc. | ||
| Denise L. Ramos | Director | Former Chief Executive Officer and President of ITT Inc. | ||
| Clayton S. Rose | Director | Baker Foundation Professor of Management Practice at Harvard Business School | ||
| Michael D. White | Director | Former Chairman, President, and Chief Executive Officer of DIRECTV | ||
| Thomas D. Woods2 | Director | Former Vice Chairman and Senior Executive Vice President of Canadian Imperial Bank of Commerce; Former Chairman, Hydro One Limited | ||
| Maria T. Zuber | Director | Vice President for Research and E.A., Griswold Professor of Geophysics, MIT | 
| Name | Position with Banc of America Preferred Funding Corporation | Principal Occupation | ||
| John J. Lawlor | Director and President | Managing Director, Municipal Markets and Public Sector Banking Executive of BofA Securities, Inc. and Bank of America, National Association | ||
| James Duffy | Managing Director | Director; MBAM BFO, The CFO Group of Bank of America, National Association | ||
| Michael I. Jentis | Managing Director | Managing Director, Head of Sales – Public Finance of BofA Securities, Inc. and Bank of America, National Association | ||
| Mona Payton | Managing Director | Managing Director, Municipal Markets Executive for Short-Term Trading of BofA Securities, Inc. and Bank of America, National Association | ||
| Edward J. Sisk | Director and Managing Director | Managing Director, Public Finance Executive of BofA Securities, Inc. and Bank of America, National Association | ||
| John B. Sprung | Director | Corporate Director | ||
| David A. Stephens | Director and Managing Director | Managing Director, Executive for Public Finance and Public Sector Credit Products of BofA Securities, Inc. and Bank of America, National Association | 
| TRADE DATE | BUY/SELL | QUANTITY | PRICE | EXECUTION | ||||||||
| 04/26/2022 | B | 400 | $ | 12.17 | OTC | |||||||
| 04/26/2022 | B | 100 | $ | 12.17 | OTC | |||||||
| 04/26/2022 | B | 75 | $ | 12.18 | OTC | |||||||
| 04/26/2022 | S | 75 | $ | 12.18 | BATS X | |||||||
| 04/26/2022 | S | 100 | $ | 12.17 | NYSE | |||||||
| 04/26/2022 | S | 400 | $ | 12.17 | NYSE | |||||||
| 04/28/2022 | B | 270 | $ | 12.3106 | OTC | |||||||
| 04/29/2022 | S | 270 | $ | 12.2793 | OTC | |||||||
| 06/16/2022 | S | 1,239 | $ | 11.4734 | OTC | |||||||
| 06/17/2022 | B | 808 | $ | 11.51 | OTC | |||||||
| 06/17/2022 | B | 431 | $ | 11.51 | OTC | |||||||
| 07/08/2022 | B | 4,075 | $ | 12.2012 | OTC | |||||||
| 07/11/2022 | S | 300 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 348 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.32 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.3 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.3 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.3 | OTC | |||||||
| 07/11/2022 | S | 99 | $ | 12.31 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.3 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.29 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.28 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.28 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.27 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.28 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.27 | OTC | |||||||
| 07/11/2022 | S | 328 | $ | 12.27 | OTC | |||||||
| 07/11/2022 | S | 100 | $ | 12.28 | OTC | |||||||
| 07/11/2022 | S | 200 | $ | 12.27 | OTC | |||||||
| 08/29/2022 | B | 700 | $ | 12.0965 | OTC | |||||||
| 08/29/2022 | S | 100 | $ | 11.9701 | OTC | |||||||
| 08/29/2022 | S | 100 | $ | 11.98 | OTC | |||||||
| 08/29/2022 | S | 200 | $ | 11.9701 | OTC | |||||||
| 08/29/2022 | S | 100 | $ | 11.98 | OTC | |||||||
| 08/29/2022 | S | 200 | $ | 11.9701 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 25 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 20 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 49 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 44 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 1,400 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 97 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 38 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 800 | $ | 11.66 | OTC | 
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 300 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | B | 827 | $ | 11.65 | OTC | |||||||
| 09/13/2022 | S | 827 | $ | 11.65 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 20 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 97 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 38 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 44 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 300 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 800 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 49 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 25 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 100 | $ | 11.66 | OTC | |||||||
| 09/13/2022 | S | 1,400 | $ | 11.66 | OTC | |||||||
| 10/20/2022 | B | 36 | $ | 10.7822 | OTC | |||||||
| 10/24/2022 | S | 36 | $ | 10.5642 | OTC | |||||||
| 10/28/2022 | B | 600 | $ | 10.4 | OTC | |||||||
| 10/31/2022 | S | 500 | $ | 10.37 | OTC | |||||||
| 10/31/2022 | S | 100 | $ | 10.374 | OTC | |||||||
| 12/20/2022 | B | 1,500 | $ | 11.245 | OTC | |||||||
| 01/04/2023 | S | 1,500 | $ | 11.495 | OTC | |||||||
| 01/12/2023 | B | 100 | $ | 11.65 | OTC | |||||||
| 01/12/2023 | B | 100 | $ | 11.65 | OTC | |||||||
| 01/12/2023 | B | 38 | $ | 11.65 | OTC | |||||||
| 01/12/2023 | B | 600 | $ | 11.65 | OTC | |||||||
| 01/12/2023 | B | 100 | $ | 11.66 | OTC | |||||||
| 01/12/2023 | S | 600 | $ | 11.65 | OTC INTERNAL | |||||||
| 01/12/2023 | S | 100 | $ | 11.65 | NYSE | |||||||
| 01/12/2023 | S | 100 | $ | 11.66 | NYSE | |||||||
| 01/12/2023 | S | 100 | $ | 11.65 | NYSE | |||||||
| 01/12/2023 | S | 38 | $ | 11.65 | NYSE | |||||||
| 01/17/2023 | B | 3,366 | $ | 11.7973 | OTC | |||||||
| 01/18/2023 | S | 3,357 | $ | 11.8873 | OTC | |||||||
| 01/19/2023 | S | 9 | $ | 11.8294 | OTC | |||||||
| 03/28/2023 | B | 200 | $ | 11.43 | OTC | |||||||
| 03/28/2023 | S | 200 | $ | 11.43 | OTC INTERNAL | |||||||
| 05/12/2023 | S | 10 | $ | 11.5008 | OTC | |||||||
| 05/15/2023 | B | 10 | $ | 11.4783 | OTC | |||||||
| 05/17/2023 | B | 4,500 | $ | 11.445 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 200 | $ | 11.44 | OTC | 
| 05/17/2023 | S | 92 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 8 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 92 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 8 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 57 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 43 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.43 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.42 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.42 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.43 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 95 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 5 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 05/17/2023 | S | 100 | $ | 11.44 | OTC | |||||||
| 06/05/2023 | B | 291 | $ | 11.26 | OTC | |||||||
| 06/05/2023 | S | 72 | $ | 11.27 | MEMX | |||||||
| 06/05/2023 | S | 26 | $ | 11.275 | OTC | |||||||
| 06/05/2023 | S | 47 | $ | 11.275 | OTC | |||||||
| 06/05/2023 | S | 73 | $ | 11.285 | NASDAQ | |||||||
| 06/05/2023 | S | 30 | $ | 11.295 | NASDAQ | |||||||
| 06/05/2023 | S | 43 | $ | 11.295 | NASDAQ | |||||||
| 06/07/2023 | B | 100 | $ | 11.32 | OTC | |||||||
| 06/07/2023 | B | 100 | $ | 11.325 | OTC | |||||||
| 06/07/2023 | B | 500 | $ | 11.32 | OTC | |||||||
| 06/07/2023 | B | 100 | $ | 11.32 | OTC | |||||||
| 06/07/2023 | B | 200 | $ | 11.32 | OTC | |||||||
| 06/07/2023 | S | 500 | $ | 11.32 | NYSE | |||||||
| 06/07/2023 | S | 200 | $ | 11.32 | NYSE | |||||||
| 06/07/2023 | S | 100 | $ | 11.32 | NYSE | |||||||
| 06/07/2023 | S | 100 | $ | 11.325 | NYSE | |||||||
| 06/07/2023 | S | 100 | $ | 11.32 | NYSE | |||||||
| 06/28/2023 | B | 100 | $ | 11.5 | OTC | |||||||
| 06/28/2023 | B | 100 | $ | 11.505 | OTC | |||||||
| 06/28/2023 | S | 100 | $ | 11.505 | NYSE | |||||||
| 06/28/2023 | S | 100 | $ | 11.5 | NYSE | |||||||
| 11/07/2023 | B | 4,175 | $ | 10.4166 | OTC | |||||||
| 11/08/2023 | S | 4,175 | $ | 10.4828 | OTC | 
| SWAPS | ||||||||||
| TRADE DATE | BUY/SELL | QUANTITY | PRICE | EXECUTION | ||||||
| 10/20/2022 | S | (1)  | (1)  | OTC | ||||||
| 10/24/2022 | B | (2)  | (2)  | OTC | ||||||
| 01/17/2023 | S | (3)  | (3)  | OTC | ||||||
| 01/18/2023 | B | (4)  | (4)  | OTC | ||||||
| 01/18/2023 | S | (4)  | (4)  | OTC | ||||||
| 01/19/2023 | B | (5)  | (5)  | OTC |